InsiderTrades

Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.

Accepted 2025-02-07 00:00:00 ET · period of report 2025-02-05 · accession 0001601830-25-000014 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-02-07 2025-02-05+ RXRX Gibson Christopher CEO, Dir C - Cnv Deriv $0.00 +40.0K 1.29M +3% $0
DM 2025-02-07 2025-02-05+ RXRX Gibson Christopher CEO, Dir S - Sale $7.90 -40.0K 1.27M -3% -$316.0K
DM 2025-02-07 2025-02-05+ RXRX Gibson Christopher CEO, Dir C - Cnv Deriv $0.00 -40.0K 5.96M -0.7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2025-02-05 C A 20,000 $0.00 1,293,156 D — —
2 Common Class A Common Stock 2025-02-06 S D 20,000 $8.12 1,273,156 D — —
3 Common Class A Common Stock 2025-02-06 C A 20,000 $0.00 1,293,156 D — —
4 Common Class A Common Stock 2025-02-05 S D 20,000 $7.68 1,273,156 D — —
5 Derivative Class B Common Stock 2025-02-06 C D 20,000 $0.00 5,936,700 D $0.00 · — to — 20,000 Class A Common Stock (F3) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
6 Derivative Class B Common Stock 2025-02-05 C D 20,000 $0.00 5,956,700 D $0.00 · — to — 20,000 Class A Common Stock (F3) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.